MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from long term
debt, net of issuance...
$96,998K
Proceeds from issuance of
common stock from...
$476K
Exercise of stock options
$58K
Net cash provided by
financing activities
$38,590K
Canceled cashflow
$58,942K
Net (decrease)
increase in cash, cash...
-$11,073K
Canceled cashflow
$38,590K
Impairment loss
$31,287K
Stock-based compensation
expense
$8,996K
Depreciation and
amortization expense
$6,809K
Loss on
extinguishment of debt
-$6,565K
Inventory
-$1,689K
Other
$1,034K
Change in third party
payor reserves
-$1,022K
Deferred tax expense
$449K
Proceeds from maturities
of marketable...
$8,500K
Proceeds from sales of
marketable securities
$875K
Repayment and principal
payments for long-term...
$54,000K
Repayment and principal
payments for long-term...
$4,447K
Finance lease principal
payments
$495K
Net cash (used in)
provided by operating...
-$32,408K
Canceled cashflow
$57,851K
Net cash used in
investing activities
-$17,255K
Canceled cashflow
$9,375K
Net loss
-$63,316K
Accounts payable and
accrued expenses
-$13,168K
Other assets and
liabilities
$9,125K
Accounts receivable
$2,558K
Change in fair value of
financial liabilities
-$2,540K
Purchases of marketable
securities
$20,177K
Purchases of property and
equipment and development...
$6,453K
Back
Back
Cash Flow
GeneDx Holdings Corp. (WGS)
GeneDx Holdings Corp. (WGS)
source: myfinsight.com